Hypersensitivity to olanzapine deca durabolin results and other ingredients; angle-closure glaucoma in history; breastfeeding; age of 18 years (effectiveness and safety have been established); lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.
Use in pregnancy and breast-feeding
women should be informed of the need to inform the doctor about the ensuing or planned pregnancy during therapy with olanzapine -Teva. Due to the limited experience of the use of olanzapine in pregnancy drug Olanzapine -Teva be used to treat pregnant women only if the potential benefit of therapy for the mother outweighs the potential risk to the fetus.
Olanzapine is excreted in breast milk. If necessary, use of the drug Olanzapine -Teva breastfeeding should be discontinued.
Dosing and Administration
Inside, regardless of meals. In schizophrenia, the recommended initial dose – 10 mg 1 time per day. For the treatment of acute manic episodes in bipolar disorder recommended initial dose – 15 mg 1 time a day (when used as monotherapy) or 10 mg 1 time per day (using combinations with drugs lithium or valproic acid). to prevent recurrence of bipolar disorder recommended initial dose – 10 mg 1 time a day.in the treatment of schizophrenia, acute manic episodes in bipolar disorder and for the prevention of recurrence of bipolar disorder dose of olanzapine selected individually depending on the clinical status of the patient and can vary in the range of 5-20 mg 1 time per day. Increasing the dose is higher than the standard (15 mg 1 time per day) is recommended only after a clinical examination of the patient.Increasing the dose should be gradually, at intervals of at least 24 hours. Reduction of the starting dose is recommended in patients with a combination of factors (female patients, elderly, non-smoking), which may contribute to a slowdown olanzapine metabolism. Elderly patients, as well as in renal failure severe degree or liver failure moderate drug is used in an initial dose of 1 mg five times a day.
The frequency of side deca durabolin results effects is classified in accordance with the recommendations of the World Health Organization: very often – at least 10%: often – at least 1% but less than 10%; infrequently – at least 0.1% but less than 1%: rarely – not less than 0.01% but less than 0.1.%: very rarely – less than 0.01%, including individual messages From the blood and lymphatic system: often – eosinophilia; rarely – leukopenia; very rarely – thrombocytopenia, neutropenia. On the part of metabolism: often – increase in body weight; often – increased appetite; unknown frequency – the development or exacerbation of diabetes mellitus, diabetic ketoacidosis, diabetic coma, including deaths. From the nervous system: very often – drowsiness; often – dizziness, akathisia, parkinsonism, dyskinesia, gait disturbance (in patients with dementia of Alzheimer’s type); rarely – extrapyramidal disturbances (mainly with high doses); very rarely – sweating, insomnia, tremor, anxiety, nausea; unknown frequency – neuroleptic malignant syndrome (NMS), dystonia (including oculogyric crisis), tardive dyskinesia. On the part of the cardiovascular system: often – orthostatic hypotension; infrequently – bradycardia, prolongation of the QT interval;unknown frequency – ventricular tachycardia / ventricular fibrillation; sudden death, pulmonary embolism, deep vein thrombosis. From the digestive system: often – dryness of the oral mucosa, constipation (m-anticholinergic effect); very rarely – hepatitis (including hepatocellular, cholestatic or mixed), pancreatitis. Skin and subcutaneous tissue disorders: rarely – photosensitivity reaction; rarely -kozhnaya rash;very rare – alopecia. From the musculoskeletal system: very rarely – rhabdomyolysis. From the urogenital system: Infrequent – urinary incontinence; very rarely – priapism, urinary retention. laboratory parameters: often – increased prolactin concentration in the blood plasma *; often – increasing the concentration of glucose, cholesterol and triglycerides in the blood plasma, glycosuria, transient increase in activity of “liver” enzymes (aspartate aminotransferase (ACT) and alanine aminotransferase (ALT)); infrequently -increasing activity of creatine phosphokinase (CK); very rarely – increased activity of alkaline phosphatase, total bilirubin and concentration. * The increase in prolactin concentration in blood plasma – poorly marked, having a transitory nature (mean maximum concentrations of prolactin did not reach the upper limit of normal and not significantly different from placebo). Clinical manifestations of hyperprolactinemia possibly associated with olanzapine (ie, amenorrhea, galactorrhea, breast enlargement in women, gynecomastia in men) were rare. Sexual dysfunction, possibly associated with the use of olanzapine (erectile dysfunction in men, decreased libido in both men and women) are often observed. In most patients, normalization of prolactin concentrations was observed without the abolition of olanzapine. Other: often – asthenia, fatigue, peripheral edema; unknown frequency – hypothermia syndrome “cancel” (sweating, insomnia, tremor, anxiety, nausea, vomiting). Specific patient groups In elderly patients with psychosis associated with dementia: very often -tserebrovaskulyarnye disorders (stroke, transient ischemic attack) including fatalities, disturbance of gait and falling; often – urinary incontinence and pneumonia. Patients with psychosis induced by medication (an agonist of dopamine receptors) for the treatment of Parkinson’s disease: very often – increased symptoms of Parkinson’s disease and hallucinations. In patients with bipolar mania, olanzapine in combination with lithium preparations or valproevoy acid: very often – increased body mass index, dryness of the oral mucosa, increased appetite, tremor; often – a speech disorder. Overdose Symptoms: tachycardia, agitation / aggressiveness, dysarthria, various extrapyramidal disorder and breach of varying degrees of consciousness (from sedation to coma), delirium, convulsions, NSA, respiratory depression, aspiration, hypertension or hypotension, ventricular tachycardia (less than 2% of overdose), cardiac arrest and breathing. The minimum dose for acute overdose fatalities was 450 mg, the maximum dose of an overdose of a favorable outcome (survival) – 1500 mg. Treatment: the deca durabolin results specific antidote does not exist. Artificially induce vomiting is not recommended. Showing Standard detoxification methods (ie gastric lavage, administration of activated charcoal). Simultaneous administration of activated charcoal reduces the bioavailability of olanzapine taken by mouth, by 50-60%. Symptomatic treatment according to clinical status and control functions of the vital organs, including the correction of hypotension, vascular collapse and support of respiratory function. Do not use epinephrine, dopamine, and other sympathomimetic which are agonists of the beta-adrenergic receptors, as last stimulation may worsen hypotension. steroidi anabolizzanti effetti collaterali andriol prezzo steroidi anabolizzanti shop